KR20120101588A - 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료 - Google Patents

탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료 Download PDF

Info

Publication number
KR20120101588A
KR20120101588A KR1020127020579A KR20127020579A KR20120101588A KR 20120101588 A KR20120101588 A KR 20120101588A KR 1020127020579 A KR1020127020579 A KR 1020127020579A KR 20127020579 A KR20127020579 A KR 20127020579A KR 20120101588 A KR20120101588 A KR 20120101588A
Authority
KR
South Korea
Prior art keywords
modafinil
carbonic anhydrase
therapeutically effective
effective amount
topiramate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127020579A
Other languages
English (en)
Korean (ko)
Inventor
릴랜드 윌슨
피터 탐
토마스 나자리안
찰스 에이치. 보든
Original Assignee
비버스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120101588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 비버스 인크. filed Critical 비버스 인크.
Publication of KR20120101588A publication Critical patent/KR20120101588A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127020579A 2010-01-07 2011-01-07 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료 Withdrawn KR20120101588A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29312910P 2010-01-07 2010-01-07
US61/293,129 2010-01-07

Publications (1)

Publication Number Publication Date
KR20120101588A true KR20120101588A (ko) 2012-09-13

Family

ID=44306177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127020579A Withdrawn KR20120101588A (ko) 2010-01-07 2011-01-07 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료

Country Status (13)

Country Link
US (3) US20110224196A1 (enExample)
EP (1) EP2521546A4 (enExample)
JP (1) JP2013516488A (enExample)
KR (1) KR20120101588A (enExample)
CN (1) CN102781446A (enExample)
AU (1) AU2011203970A1 (enExample)
BR (1) BR112012016799A2 (enExample)
CA (1) CA2786026A1 (enExample)
CL (1) CL2012001844A1 (enExample)
IL (1) IL220552A0 (enExample)
IN (1) IN2012DN06616A (enExample)
MX (1) MX2012007813A (enExample)
WO (1) WO2011085256A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3179999A2 (en) * 2014-08-14 2017-06-21 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
US20160367503A1 (en) * 2015-06-20 2016-12-22 Cary Erwin Fechter Combination Medication for Neuro-Degenerative Diseases
CA2991529C (en) 2015-07-08 2021-01-05 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
AU2017261680B2 (en) 2016-05-11 2019-06-27 Apnimed, Inc. Sultiame for the treatment of sleep apnea
WO2020047603A1 (en) * 2018-09-06 2020-03-12 Monash University Method of treating a sleep breathing disorder
WO2021091902A1 (en) * 2019-11-04 2021-05-14 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US12046341B2 (en) 2021-10-05 2024-07-23 Bradford Rabin Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea
WO2025207125A1 (en) * 2024-03-26 2025-10-02 The Regents Of The University Of California Combination pharmacological interventions for obstructive sleep apnea

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021A (en) * 1847-03-20 Jambs haworth
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2706767B1 (enExample) * 1993-06-22 1995-09-08 Lafon Labor
EP1158973B1 (en) * 1999-02-24 2005-05-04 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US20040229943A1 (en) * 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations
EP1516869A1 (en) * 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP2343073A3 (en) * 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
SE0400378D0 (sv) * 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
JP2009508854A (ja) * 2005-09-16 2009-03-05 セリューサイエンス アーベー 睡眠時呼吸障害の予防及び治療方法及び手段
EP2556830A1 (en) * 2006-12-19 2013-02-13 University Of Virginia Patent Foundation Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
CA2683697C (en) * 2007-04-09 2016-08-16 Sepracor Inc. Methods and compositions for treating sleep-related breathing disorders
AU2008259588A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders

Also Published As

Publication number Publication date
EP2521546A2 (en) 2012-11-14
MX2012007813A (es) 2012-08-01
BR112012016799A2 (pt) 2019-10-08
CA2786026A1 (en) 2011-07-14
JP2013516488A (ja) 2013-05-13
EP2521546A4 (en) 2013-06-26
CN102781446A (zh) 2012-11-14
US20110224196A1 (en) 2011-09-15
IN2012DN06616A (enExample) 2015-10-23
US20150231110A1 (en) 2015-08-20
AU2011203970A1 (en) 2012-07-12
WO2011085256A3 (en) 2011-11-03
CL2012001844A1 (es) 2013-03-22
IL220552A0 (en) 2012-08-30
US20140094511A1 (en) 2014-04-03
WO2011085256A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
KR20120101588A (ko) 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
US20230233521A1 (en) Escalating dosing regimen for effecting weight loss and treating obesity
US8536138B2 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
US20240139224A1 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP2008543813A5 (enExample)
AU2014213552B2 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
AU2016203699A1 (en) Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
AU2014202124A1 (en) Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301